Eric Joseph
Stock Analyst at JP Morgan
(1.70)
# 1,187
Out of 5,180 analysts
125
Total ratings
38.82%
Success rate
-4.46%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $3.06 | +259.48% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $33.58 | +45.92% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $24.22 | +89.93% | 4 | Oct 9, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $70 → $71 | $98.64 | -28.02% | 7 | Sep 25, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $84.93 | -24.64% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.62 | +93.37% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.39 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $8.02 | -12.72% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $68.75 | -2.55% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.13 | - | 4 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.32 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $15.48 | +93.80% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $9.02 | +55.21% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $24.37 | +55.93% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.46 | +415.70% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $6.83 | +148.90% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $10.77 | +94.99% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $12.97 | -22.90% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.49 | +906.71% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.70 | +122.22% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $17.17 | -35.93% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $20.81 | +380.54% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.19 | +128.31% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $5.65 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $52.79 | -79.16% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $28.44 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $5.82 | +1,961.86% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.81 | +3,743.69% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $12.08 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.38 | +552.17% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.41 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.33 | +1,702.58% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.90 | +233.33% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.26 | +4,129.14% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $3.06
Upside: +259.48%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $33.58
Upside: +45.92%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $24.22
Upside: +89.93%
Revolution Medicines
Sep 25, 2025
Maintains: Overweight
Price Target: $70 → $71
Current: $98.64
Upside: -28.02%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $84.93
Upside: -24.64%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.62
Upside: +93.37%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.39
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $8.02
Upside: -12.72%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $68.75
Upside: -2.55%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.13
Upside: -
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.32
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $15.48
Upside: +93.80%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $9.02
Upside: +55.21%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $24.37
Upside: +55.93%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $4.46
Upside: +415.70%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $6.83
Upside: +148.90%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $10.77
Upside: +94.99%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $12.97
Upside: -22.90%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.49
Upside: +906.71%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.70
Upside: +122.22%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $17.17
Upside: -35.93%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $20.81
Upside: +380.54%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.19
Upside: +128.31%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $5.65
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $52.79
Upside: -79.16%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $28.44
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $5.82
Upside: +1,961.86%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.81
Upside: +3,743.69%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $12.08
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.38
Upside: +552.17%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.41
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.33
Upside: +1,702.58%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.90
Upside: +233.33%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.26
Upside: +4,129.14%